Back to top
more

ALPS Medical Breakthroughs ETF: (SBIO)

(Delayed Data from NYSE) As of Sep 6, 2024 02:39 PM ET

$35.93 USD

35.9315
3,277

-0.48 (-1.31%)

Volume: 3,277

Zacks ETF Rank

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

5 - Strong Sell of 5         5

After-Market: $35.94 +0.01 (0.02 %) 5:56 PM ET

Zacks News

Sanghamitra Saha headshot

Beyond Biotech, 5 ETFs Up At Least 10% in Q4

Apart from biotech, these ETFs are seeing solid momentum in the ongoing quarter.

Neena Mishra headshot

Why Biotech ETFs are Surging to New Highs

increasing M&A deals and cutting edge therapies are driving biotech ETFs higher

Sweta Killa headshot

Biotech ETFs Hit New Highs on Deal Activities

Following the new deals in the healthcare space, a few biotech ETFs hit new highs.

Sweta Jaiswal, FRM headshot

A Guide to Biotech ETF Investing

Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to work in favor of the biotech market.

Sweta Killa headshot

Russell 2000 Hits New 1-Year High: 5 Best-Performing ETFs

Small caps started to show their momentum and are trying to catch up with the large cap peers. The Russell 2000 Index hit a new 52-week high.

Sweta Killa headshot

5 ETFs That Deserve Special Thanks in 2019

These ETFs deserve special thanks and attention going into the New Year.

Sweta Killa headshot

Healthcare Sector Outperforming: 5 Best ETFs & Stocks QTD

Healthcare bounced back with an outperformance starting the fourth quarter.

The Zacks Analyst Blog Highlights: SEA, SBIO, WOOD, CRAK and FTXL

The Zacks Analyst Blog Highlights: SEA, SBIO, WOOD, CRAK and FTXL

Sweta Killa headshot

5 Best Sector ETFs of October With Double-Digit Returns

October has been kind to the U.S. stock market thanks to U.S.-China trade progress, better-than-expected corporate earnings and a third Fed rate cut.

Sweta Killa headshot

Healthcare ETFs Win in October: Here's Why

The healthcare sector, which has been the second-worst performer among the 11 major S&P 500 sectors this year, took the center stage this month with some outperformance compared to other sectors.

Panel Of Zacks Experts headshot

Navigating The Healthcare Industry: Science Fiction Turns to Reality

Kevin Cook joins us to help walk us through the maze that is the healthcare industry. We touch on everything from the hottest trends all the way down to how to pick a winning stock!

Sweta Killa headshot

Biotech ETFs Surge on a Flurry of Positive News

The biotech sector got a boost over the past week from a flurry of positive news including trial results and deal activities.

Sweta Jaiswal, FRM headshot

Top-Performing Biotech ETFs YTD

Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to boost the biotech stocks. Accordingly, we take a look at biotech ETFs gaining more than 10% year to date.

Neena Mishra headshot

Why These Innovative Biotech ETFs Are Soaring

Strong M&A activity has sent shares of many small, innovative biotech companies surging

Sweta Killa headshot

Pfizer-Array Biopharma Deal Bump Up Biotech ETFs

Pfizer struck a deal to acquire the cancer drugmaker Array Biopharma for $11 billion in an all-cash consideration.

Sanghamitra Saha headshot

Markets & ETFs Digest Trade Spat: Is It a Dead-Cat-Bounce?

Though markets rallied probably on the undervalued status and a still-steady US economy, rising recessionary fears and full-scale trade war risks should brighten the appeal of safer ETFs.

Sweta Jaiswal, FRM headshot

Biotechnology Market on a Tear: 5 ETFs in Spotlight

Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.

Sanghamitra Saha headshot

Top ETF Stories of February

Inside the top ETF events of the month of February.

Sweta Killa headshot

Biotech ETFs Jump on Roche-Spark Deal

The news of Roche-Spark Deal has triggered speculations of merger wave in the gene therapy industry and pushed the biotech ETFs higher.

The Zacks Analyst Blog Highlights: SBIO, ISMD, JKL, JSML and JKK

The Zacks Analyst Blog Highlights: SBIO, ISMD, JKL, JSML and JKK

Sweta Killa headshot

Small Caps Taking Charge of the Bulls: 6 ETF Winners YTD

we have presented six top performing small-cap ETFs of the current rally that have gained in double digits and will continue their outperformance.

Sanghamitra Saha headshot

Top ETFs of Last Week

These ETFs have had a strong last week.

Sanghamitra Saha headshot

6 Wining ETF Areas From a Late Santa Rally

These sector ETFs have made the most of the start of this Santa Rally.

Sweta Killa headshot

Sarepta Pharma Pushes Two Biotech ETFs to New Highs

The encouraging early trial results for a gene therapy for Duchenne muscular dystrophy pushed Sarepta Therapeutics and few biotech ETFs to new highs.

    Sweta Killa headshot

    5 Small-Cap ETFs & Stocks Crushing Russell 2000

    We have presented five ETFs & stocks that have easily crushed the Russell 2000 index this year and are likely to continue their strong performance.